BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic ...
Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue ...
Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback